King’s College Hospital part of UK trial of Retinal Implant.

Exciting new development for patients with Retinitis Pigmentosa - a degenerative eye disease.

CGI Skull showing retinal implant

King’s College Hospital – part of King’s Health Partners Academic Health Science Centre - is one of two centres taking part in a UK trial of a retinal implant for patients with retinitis pigmentosa, a degenerative eye condition that gets worse over time.

The team at King’s, led bv eye surgeon Mr Tim Jackson, successfully carried out retinal implant surgery on a patient last month, in tandem with Professor Robert MacLaren at the Oxford Eye Hospital. Mr Jackson is a consultant retinal surgeon at King's College Hospital, and also a Senior Clinical Lecturer at King's College London.

Both patients – who had no vision prior to surgery - are doing well. They were able to detect light immediately after the retinal implant microchip was activated. Further testing has shown that both patients are able to locate white objects on a dark background. Over the coming months, the patients will undergo further testing as they come to adjust to the microchip.

The UK trial of the device is set to include 12 patients in total, and is being led by the two centres. Mr Tim Jackson and Professor Robert MacLaren commented: “We are excited to be involved in this pioneering subretinal implant technology and to announce the first patients implanted in the UK were successful. The visual results of these patients exceeded our expectations. This technology represents a genuinely exciting development and is an important step forward in our attempts to offer people with retinitis pigmentosa a better quality of life.”

King’s patient Robin Millar, a 60 year old music producer from London who was one of the two patients to be implanted, said: “Since switching on the device I am able to detect light and distinguish the outlines of certain objects. I have even dreamt in very vivid colour for the first time in 25 years, so a part of my brain which had gone to sleep has woken up ! I feel this is incredibly promising for future research and I’m happy to be contributing to this legacy.”

Retina Implant’s subretinal implant technology has been in clinical trials for more than six years. Patients involved in Retina Implant’s clinical trials have received a 3x3 mm2 microchip with 1,500 electrodes implanted below the retina. Results from the Company’s first human clinical trial published in Proceedings of the Royal Society B in November 2010 showed placement of the implant below the retina, in the macular region, provided optimum visual results allowing patients to recognise foreign objects and to read letters to form words.

The second human clinical trial, in which patients were implanted with Retina Implant’s new wireless device in Germany, beginning in May 2010, indicated even better visual acuity. The multi-centre phase of this trial was expanded late last year to include two additional sites in Germany, Hong Kong and the UK. Sites in Italy and Hungary are also under agreement to participate.

Data from the first nine patients implanted in Germany in this current trial indicate the best visual acuity to-date, with the majority of patients experiencing restoration of useful vision in daily life. The vast majority of patients are experiencing visual perception indoors and outdoors in both dim and bright environments. Additionally, patients have reported the ability to see objects 30 feet away and to read numbers on a pair of dice.

Important information – selection criteria for the trial at King’s College Hospital
Trial recruitment in the UK is now open and Mr. Tim Jackson, Consultant Ophthalmic and Retinal Surgeon at King’s College Hospital, will be specifically looking for patients who meet the following criteria:

  • Aged 18 to 78 years
  • A UK citizen
  • Total, or almost total sight loss due to retinitis pigmentosa
  • Blind now, but previously had at least 12 years of vision
    Please note that anyone who has enough vision to see shapes or objects will NOT be eligible.

If you think that you, or someone you know, may fit this criteria, and would like to apply to take part in the London part of the retina implant trial, please obtain a referral from your GP or ophthalmologist to Tim Jackson at King’s College Hospital. The Eye Department of the Hospital will then arrange an initial consultation. If you may be suitable for a retinal implant then you may subsequently be offered an appointment to discuss the trial itself.

Not all patients who wish to take part in the trial will be eligible to join it.

For further information please contact:
Chris Rolfe
Head of Communications
Extension: +44 (0)20 3299 3006

Notes to editors

1. King’s College Hospital NHS Foundation Trust is one of the UK’s largest and busiest teaching hospitals, with nearly 7,000 staff providing around 1,000, 000 patient contacts a year. King’s has a unique profile, with a full range of local hospital services for people in the London boroughs of Lambeth and Southwark as well as specialist services to patients from further afield. The Trust is recognized internationally for its work in liver disease and transplantation, neurosciences, cardiac, haemato-oncology, stroke and major trauma. King’s also plays a key role in the training and education of medical, nursing and dental students with its academic partner, King’s College London. For more information, visit

2. King’s College Hospital and Guy’s and St Thomas’ are both part of King’s Health Partners Academic Health Sciences Centre (AHSC), a pioneering collaboration between King’s College London, and Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts.

King’s Health Partners is one of only five AHSCs in the UK and brings together an unrivalled range and depth of clinical and research expertise, spanning both physical and mental health. Our combined strengths will drive improvements in care for patients, allowing them to benefit from breakthroughs in medical science and receive leading edge treatment at the earliest possible opportunity.

For more information, visit